Movers and SHAKERS
GID BIO CEO Dr. William (Bill) Cimino delivers a formal corporate overview, followed by a Q & A session moderated by a Noble Capital Markets equity research representative.
Return to the Investor Forum Event Page
GID BIO has developed a tissue processing technology that enables point-of-care cellular therapies using a patient’s own cells for treatment of significant degenerative diseases, including osteoarthritis, peripheral vascular disease, degenerative diseases of the lung, and Parkinson’s Disease. Our biologic approach to therapy generates clinical results not achievable using drugs or devices.
Our device technology isolates and separates the healing stromal and vascular cells, including stromal progenitor cells, from the patient’s own adipose tissue at point-of-care, to leverage the most powerful healing capability known – the body’s innate and natural ability to heal itself. Our FDA-approved Phase IIb study showed that 85% of subjects responded greater than placebo at 1 year, with a median 87 % improvement in pain, stiffness, and function.
We have successfully completed Phase I and Phase II efforts and have launched an FDA-approved Pivotal/Phase III clinical trial for our technology and lead indication – degenerative osteoarthritis of the knee, the largest market opportunity in musculoskeletal disease.
We have a significant clinical pipeline for treatment of degenerative diseases – with pilot human data and development plans for osteoarthritis of the hands/spine, diabetic ulcers, and Parkinson’s Disease.